Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Kur Research

Neither a doctor nor a teaching hospital

Research payments

$636,459

35 payments

Through program year 2025, Kur Research is reported as receiving $636,459 in research payments, across 35 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $221,538 18
2024 Research $365,441 12
2023 Research $32,180 4
2022 Research $17,300 1

Breakdown

Who paid Research payments · program years 2022–2025
  1. Sekisui Diagnostics LLC $266,806 3 payments
  2. Eli Lilly and Company $182,467 9 payments
  3. AstraZeneca Pharmaceuticals LP $114,483 6 payments
  4. GlaxoSmithKline, LLC. $42,623 13 payments
  5. OraSure Technologies Inc. $30,080 4 payments
Studies the money was for Research payments · program years 2022–2025
  1. Clinical Evaluation of the Sekisui Osom Covid-19 Antigen Home Test $143,006 1 payment
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $126,487 5 payments
  3. Human Factors and Clinical Validation of the SEKISUI OSOM Flu SARS-CoV-2 Combo Home Test in Anterior Nares Nasal Samples For Over-the-Counter (OTC) Use $123,800 2 payments
  4. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $50,086 2 payments
  5. Sample Acquisition and Testing Protocol for Development of Tests to Detect Antigens to COVID-19 and Influenza A and B $30,080 4 payments
  6. A Phase 2B Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone Or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity Or Overweight With Type 2 Diabetes $26,977 2 payments
  7. Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD $26,625 2 payments
  8. 17 B-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatme $24,707 5 payments
  9. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $20,772 1 payment
  10. Taltz Psa Observational Study $19,400 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record